In this study, we systematically investigated the anti-CRC mechanisms of CDN using a multi-scale approach integrating network pharmacology, proteomic profiling, molecular docking, and in vitro/in vivo functional assays. This evidence concerns the gene NT5C and colorectal carcinoma.